Lung Cancer
FDA Approves Ensartinib in ALK-Positive NSCLC
The FDA has granted ensartinib approval for adult patients with ALK-positive non–small cell lung cancer.
Read More
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Listen
Sequencing and Management Considerations for ALK TKIs in NSCLC
During a Case-Based Roundtable® event, Chul Kim, MD, moderated a discussion on current use of ALK TKIs in lung cancer in the second article of a 2-part series.
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Revolutionizing Lung Cancer Treatment: Advancements Offer New Hope
Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed hope to millions worldwide.
Zenocutuzumab Now FDA-Approved in NRG1+ NSCLC and Pancreatic Cancer
With this approval, zenocutuzumab is the first FDA-approved therapy for patients with NRG1 fusion tumors.
